Future work will include developing therapeutics under the control of the survivin promoter for the treatment of GBM, potentially coupled as part of an HAdV-C5/D49K-pseudotyped vector to maximise the uptake and activity in GBM cells. The gene discussed is BIRC5; the disease is glioblastoma.